Condition
Ivonescimab
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06940518Phase 2RecruitingPrimary
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07385001Phase 1Recruiting
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
NCT07021950Phase 2Not Yet Recruiting
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Showing all 3 trials